| Literature DB >> 32750526 |
Darren W Engers1, Sean R Bollinger1, Andrew S Felts1, Anish K Vadukoot2, Charles H Williams3, Anna L Blobaum1, Craig W Lindsley4, Charles C Hong3, Corey R Hopkins5.
Abstract
The activin-like kinases are a family of kinases that play important roles in a variety of disease states. Of this class of kinases, ALK2, has been shown by a gain-of-function to be the primary driver of the childhood skeletal disease fibrodysplasia ossificans progressiva (FOP) and more recently the pediatric cancer diffuse intrinsic pontine glioma (DIPG). Herein, we report our efforts to identify a novel imidazo[1,2-a]pyridine scaffold as potent inhibitors of ALK2 with good in vivo pharmacokinetic properties suitable for future animal studies.Entities:
Keywords: ALK2; ALK3; Activin-like kinase inhibitors; BMP inhibitors
Mesh:
Substances:
Year: 2020 PMID: 32750526 PMCID: PMC7494637 DOI: 10.1016/j.bmcl.2020.127418
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823